RecruitingPeripheral Arterial Disease
MitoQ Treatment of Claudication: Myofiber and Micro-vessel Pathology
Eligible age
21+ yrs
Accepts
All genders
Locations
1 state
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
In our research, we are delving into whether taking MitoQ for six months can improve the symptoms and function of people diagnosed with peripheral artery disease, especially those who suffer from leg pain while walking, known as intermittent claudication. We will be checking if MitoQ helps people with claudication walk better, be more active every day, feel better about their lives, and if it enhances the health of their leg muscles.
Sponsor: University of Nebraska
You may qualify if…
- ✓ 1. a positive history of chronic claudication
- ✓ 2. exercise-limiting claudication established by history and direct observation during a screening walking test administered by the evaluating vascular surgeon
- ✓ 3. documented lower extremity arterial occlusive disease based on ankle/brachial index measurements and/or arterial imaging
- ✓ 4. stable blood pressure, lipid and diabetes regimens and risk factor control for 6 weeks.
You may not qualify if…
- ✕ 1. rest pain or tissue loss due to PAD (Fontaine stage III and IV)
- ✕ 2. acute lower extremity ischemic event
- ✕ 3. walking capacity significantly and primarily limited by conditions other than claudication including leg (joint/musculoskeletal, neurologic) and systemic (heart, lung disease) pathology.
Where it's recruiting
Nebraska
Omaha
Source: ClinicalTrials.gov · NCT06409949 · last updated 2026-02-24